Journal of Cancer Science & Therapy
ISSN / EISSN : 1948-5956 / 1948-5956
Published by: OMICS Publishing Group (10.4172)
Total articles ≅ 878
Latest articles in this journal
Journal of Cancer Science & Therapy, Volume 11; https://doi.org/10.4172/1948-5956.1000574
Journal of Cancer Science & Therapy, Volume 11, pp 034-037; https://doi.org/10.4172/1948-5956.1000580
Journal of Cancer Science & Therapy, Volume 11; https://doi.org/10.4172/1948-5956-c1-160
Journal of Cancer Science & Therapy, Volume 11; https://doi.org/10.4172/1948-5956-c1-159
Journal of Cancer Science & Therapy, Volume 11, pp 009-013; https://doi.org/10.4172/1948-5956.1000575
Current standard cancer drugs and various synthetic agents exhibit high toxic activities against cancer cells, but doubts have been raised as to their long term stability and safety. Generally, these synthetic agents are relatively expensive; this makes them not affordable to many people. Although most probiotic anticancer therapies are in preclinical development phase, due to their low efficacy and poor selectivity, gradual replacement of current cancer drugs and other synthetic agents with appropriate biotherapeutic substances is proposed to overcome the challenges associated with the use of these synthetic agents. These probiotics can have an effect on other aspects of human health and hence make life worth living during and after cancer treatment. At present, most anticancer research regarding probiotic microbes focuses on Lactobacillus and Bifidobacteria, but other probiotics are involved. This review describes the properties of probiotic bacteria as potential biotherapeutics to supplement current standard anti-cancer therapies. The reader will gain an overview of different probiotics tested so far with respective bioassays used in probiotic anti-cancer drug discovery. Note, Not all therapies used generated an effective response in all patients and that use of probiotic therapies provides negligible if any, detrimental side effects.
Journal of Cancer Science & Therapy, Volume 11, pp 043-049; https://doi.org/10.4172/1948-5956.1000582
Background: Breast cancer, the most frequent cancer among women, is also the leading cause of cancerrelated deaths among women. In resource poor settings, it is often diagnosed late due to low rates of screening. To more successfully support breast cancer prevention, it is vital to know the reason women do not utilize breast cancer screening. Hence, this study assessed utilization of breast cancer screening services and associated factors among women attending Centre Hospital University Kigali (CHUK), Rwanda.Methods: A cross-sectional study was conducted among 384 women who were selected consecutively as they came to the hospital. A pre-tested structured questionnaire was used to collect data. Both descriptive and inferential statistics were utilized during data analysis.Results: The utilization of breast cancer screening was low at 35.2%. After running multivariable analysis the following factors were independently associated with utilization: respondents aged 30-39 years [AOR=3.62; 95%CI=1.80-7.29; p0.001], high level of screening awareness [AOR=17.23; 95%CI=7.62 - 38.99; p<0.001] and respondents who agreed that there was regular follow up by nurses at the health facilities [AOR=3.05; 95%CI=1.31 - 7.10; p=0.010].Conclusion: Majority of women had not had screening for breast cancer of which a significant number were not even aware of breast cancer screening. The study found different factors associated with utilization of breast cancer screening including awareness. There is need to intensify efforts towards promoting awareness and screening of breast cancer.
Journal of Cancer Science & Therapy, Volume 11, pp 050-056; https://doi.org/10.4172/1948-5956.1000583
Journal of Cancer Science & Therapy, Volume 11; https://doi.org/10.4172/1948-5956-c1-158
Journal of Cancer Science & Therapy, Volume 11, pp 057-062; https://doi.org/10.4172/1948-5956.1000584
Objective: Immunohistochemical fatty acid synthase expression is a prognostic marker in several cancers and is related to cancer aggressiveness. Here, we analyzed fatty acid synthase expression as an indicator of adjuvant chemotherapy for distal bile duct and ampullary cancer cases.Methods: Forty-three cases of distal bile duct cancer and thirty-seven ampullary cancer cases resected between 2000 and 2017 were examined. We investigated immunohistochemical fatty acid synthase expression in resected specimens and the involvement of lymph nodes. We compared these findings with patient prognosis using medical history of postoperative adjuvant chemotherapy. Patient survival was expressed by the Kaplan-Meyer method and analyzed by a log-rank test.Results: There were twenty-two fatty acid synthase-positive cases for distal bile duct cancer and seventeen for ampullary cancer. For distal bile duct cancer cases, the relapse-free survival and overall survival of fatty acid synthase-positive cases were shorter than those for fatty acid synthase-negative cases (p=0.0094 and p=0.0327, respectively). For ampullary cancer cases, the relapse-free survival and overall survival of fatty acid synthase-positive cases were also shorter than those for fatty acid synthase-negative cases (p=0.0225 and p=0.0103, respectively). Adjuvant chemotherapy occurred in twelve of the twenty-two fatty acid-positive distal bile duct cancer cases and in eight of the seventeen fatty acid-positive ampullary cancer cases. Relapse-free survival and overall survival of cases with adjuvant chemotherapy did not differ from those without adjuvant chemotherapy in both distal bile duct cancer and ampullary cancer.Conclusion: Although fatty acid synthase expression was a prognostic factor in bile duct cancer and ampullary cancer, it was not an indicating marker for adjuvant chemotherapy.
Journal of Cancer Science & Therapy, Volume 11, pp 028-033; https://doi.org/10.4172/1948-5956.1000579